How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,625 results for

Intrauterine Device

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report Full Text available with Trip Pro

A large bladder stone caused by the intravesical migration of an intrauterine contraceptive device: a case report A wide variety of complications due to the extrauterine migration of intrauterine contraceptive devices have been reported in the literature. Here we describe the case of a large bladder stone formed around a migrated Copper T380A device that was neglected and detected 15 years after insertion.A 48-year-old Sri Lankan woman underwent a workup for lower urinary tract symptoms (...) and recurrent urinary tract infections over the previous 6 months. The radiographs showed a large bladder stone with an imprint of an intrauterine contraceptive device in the center of it. The device had been inserted 15 years previously. Two years after the insertion, it was considered to be missing, but our patient did not comply with the recommended follow-up. She had been completely asymptomatic until she developed lower urinary tract symptoms. After confirming the location of the stone via

2017 Journal of medical case reports

142. Chronic Systemic Toxicity Study of Copper Intrauterine Devices in Female Wistar Rats Full Text available with Trip Pro

Chronic Systemic Toxicity Study of Copper Intrauterine Devices in Female Wistar Rats BACKGROUND The aim of this study was to evaluate the chronic systemic and local toxicity of a copper intrauterine device in a rat model. MATERIAL AND METHODS Cu-IUD fragments were inserted into the uterine horns of female Wistar rats for 26 weeks (equivalent 15.42-17.33 years in humans). We tested copper at 20, 40, and 60 times the clinical dosages to study copper toxicity under severe conditions. Classic

2017 Medical science monitor : international medical journal of experimental and clinical research

143. Intravesical Migration of an Intrauterine Contraceptive Device with Secondary Calculus Formation Full Text available with Trip Pro

Intravesical Migration of an Intrauterine Contraceptive Device with Secondary Calculus Formation Intrauterine contraceptive devices (IUCDs) are a common form of reversible contraception owing to fewer systemic side effects and low cost, especially in a developing country like India. However, IUCDs are not without complications. Migration of a device into adjacent organs is the most morbid of all the documented complications. A patient who presents with a history that suggests loss (...) or disappearance of an IUCD thread associated with urinary symptoms should raise suspicions that a device may have migrated into the bladder. Physicians should also be aware of possible secondary vesical calculus formation. Further radiological investigations and appropriate management are warranted. We present a case report describing the migration of an IUCD into the bladder with secondary calculus formation.

2017 Korean journal of family medicine

144. Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion Full Text available with Trip Pro

Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion 28985748 2018 11 13 1742-4755 14 1 2017 10 06 Reproductive health Reprod Health Correction to: Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion. 126 10.1186/s12978-017-0386-2 Howard Brandon B Teva Global Medical Affairs, 41 Moores Road, Frazer, PA, 19355, USA. Brandihoward@gmail.com. Grubb ElizaBeth E Teva Global

2017 Reproductive health

145. Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management Full Text available with Trip Pro

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management Globally, endometrial cancer is the sixth leading cause of female cancer-related deaths. Non-atypical endometrial hyperplasia (EH), has a lifetime progression rate to endometrial cancer ranging from less than 5%, if simple without atypia, to 40%, if complex with atypia. Site specific, long-acting intrauterine devices (IUDs) provide fertility sparing, progestin-based EH

2017 Healthcare

146. Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion Full Text available with Trip Pro

Trends in use of and complications from intrauterine contraceptive devices and tubal ligation or occlusion Long-acting reversible contraceptives such as intrauterine devices (IUDs) are highly effective in preventing pregnancy, cost effective, and increasing in popularity. It is unclear whether changes in IUD use are associated with changes in rates of irreversible tubal sterilization. In this analysis, we evaluate changes in rates of tubal sterilization, insertion of copper or levonorgestrel

2017 Reproductive health

147. An Estimation of the Risk of Pseudotumor Cerebri among Users of the Levonorgestrel Intrauterine Device Full Text available with Trip Pro

An Estimation of the Risk of Pseudotumor Cerebri among Users of the Levonorgestrel Intrauterine Device Because of a previous association of pseudotumor cerebri (PTC) with levonorgestrel, we wished to evaluate the use of levonorgestrel-eluting intrauterine devices ("levonorgestrel intrauterine systems", LNG-IUS) in our University of Utah and Rigshospitalet PTC patients. In our retrospective series, PTC prevalence was approximately 0.18% and 0.15% in the LNG-IUS population versus 0.02% and 0.04

2017 Neuro-Ophthalmology

148. Lidocaine for Pain Control During Intrauterine Device Insertion

Lidocaine for Pain Control During Intrauterine Device Insertion Lidocaine for Pain Control During Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lidocaine for Pain Control (...) During Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03362905 Recruitment Status : Not yet recruiting First Posted : December 5, 2017 Last Update Posted : December 5, 2017 See Sponsor: Ain

2017 Clinical Trials

149. Intrauterine Device Insertion: a Step for High Satisfaction:

Intrauterine Device Insertion: a Step for High Satisfaction: Intrauterine Device Insertion: a Step for High Satisfaction: - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Intrauterine Device Insertion (...) Information provided by (Responsible Party): Mohammed Khairy Ali, Assiut University Study Details Study Description Go to Brief Summary: The intrauterine device is a safe, reliable and long-acting reversible contraceptive method. Instrumentation of lower genital mucosa during intrauterine device application provokes pain because it is highly sensitive to touch. Fear of pain associated with intrauterine device insertion is considered a barrier to use this contraception method. The classic insertion

2017 Clinical Trials

150. Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users

Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

151. Systemic effects of levonorgestrel-releasing intrauterine devices

Systemic effects of levonorgestrel-releasing intrauterine devices Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

152. Impact on the use of Levonorgestrel-realising intrauterine device (IUD) on ovarian cancer risk

Impact on the use of Levonorgestrel-realising intrauterine device (IUD) on ovarian cancer risk Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

153. Interventions to ease intrauterine device (IUD) insertion: a systematic review

Interventions to ease intrauterine device (IUD) insertion: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

154. Systematic review on intrauterine devices for the management of postpartum haemorrhage

Systematic review on intrauterine devices for the management of postpartum haemorrhage Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2019 PROSPERO

155. Early Versus Late Interval Postpartum Copper Intrauterine Device Insertion

Early Versus Late Interval Postpartum Copper Intrauterine Device Insertion Early Versus Late Interval Postpartum Copper Intrauterine Device Insertion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Early (...) Versus Late Interval Postpartum Copper Intrauterine Device Insertion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03106805 Recruitment Status : Recruiting First Posted : April 10, 2017 Last Update Posted : August 16

2017 Clinical Trials

156. Use Sonography in Patients With Intrauterine Device Presenting With Bleeding

Use Sonography in Patients With Intrauterine Device Presenting With Bleeding Use Sonography in Patients With Intrauterine Device Presenting With Bleeding - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Use (...) Sonography in Patients With Intrauterine Device Presenting With Bleeding The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03140800 Recruitment Status : Not yet recruiting First Posted : May 4, 2017 Last Update Posted : May 4

2017 Clinical Trials

157. Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery

Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03166111

2017 Clinical Trials

158. Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. (Abstract)

Vaginal misoprostol prior to intrauterine device insertion in women delivered only by elective Cesarean section: a randomized double-blind clinical trial. The current study aims to evaluate if vaginal misoprostol (400 mcg) administered prior to intrauterine device (IUD) insertion increases the ease and success of insertion among women who had delivered only by elective cesarean delivery (CD).The current study was a randomized, double-blind, placebo-controlled trial conducted in Assiut Women's

2017 Contraception Controlled trial quality: predicted high

159. Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. Full Text available with Trip Pro

Short-term copper intrauterine device placement improves the implantation and pregnancy rates in women with repeated implantation failure. To study if hysteroscopy and short-term copper intrauterine device placement (Cu-IUD) improves the pregnancy rates of women with repeated implantation failure (RIF) undergoing frozen-thawed embryo transfer (FET).Retrospective study.Medical university hospital.Infertile women with at least two implantation failures with the use of at least one good-quality (...) embryo.All patients received operative hysteroscopy in the follicular cycle, and if endometrial polyps, polypoid endometrium, or intrauterine adhesions were found they were removed. In some patients, a Cu-IUD was inserted immediately after hysteroscopy and removed after two menstrual periods before embryo implantation. All patients underwent in vitro fertilization or intracytoplasmic sperm injection and FET.Clinical pregnancy and implantation rates.A total of 440 women with a mean age of 33.42 ± 4.45

2017 Fertility and Sterility

160. Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. Full Text available with Trip Pro

Effects of injectable progestogen contraception versus the copper intrauterine device on HIV acquisition: sub-study of a pragmatic randomised controlled trial. Evidence from observational studies suggests an increased risk of HIV acquisition among women using depot medroxyprogesterone acetate (DMPA) contraception.Within the context of a South African programme to increase women's access to the intrauterine contraceptive device (IUD), we conducted a pragmatic, open-label, parallel-arm

2017 Journal of Family Planning and Reproductive Health Care Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>